News & Reports

Press Releases

Patients For Affordable Drugs Responds to Trump’s Announcement On Tariffs

WASHINGTON, DC – Following President Trump’s announcement of sweeping tariffs of up to 100% on imported brand-name prescription drugs and their ingredients, Patients For Affordable Drugs CEO Merith Basey released the following statement: “While these tariffs aim to pressure pharmaceutical corporations into U.S. manufacturing and Most Favored Nation agreements, the current MFN deals remain opaque and voluntary, and have […]

Press Releases

P4AD Expands Board Leadership, Strengthening Expertise and Momentum in the Fight to Lower Drug Prices

WASHINGTON, D.C. — Patients For Affordable Drugs today announced the addition of new leaders to its board of directors, further strengthening the organization’s expertise and continued growth. “Our new board members bring a depth of knowledge across medicine, law, public health, and business, along with patient experience — exactly the expertise this fight demands,” said Merith Basey, CEO […]

News and Reports

InsideHealthPolicy: DOJ Defends Drug Negotiation Program In Latest SCOTUS Brief

“What’s notable here is the broader signal it sends about the program’s staying power. Despite sustained opposition from the industry it’s proven durable across administrations,” a spokesperson for the group Patients for Affordable Drugs said. “This brief is the clearest signal yet that Medicare negotiation is not only being upheld, but reinforced as a central […]

Press Releases

New P4AD Analysis: Pharma Hikes Prices on Cancer Drugs, While Lobbying to Obstruct Reform

Analysis is part of a new series on Pharma-driven price hikes of essential medicines WASHINGTON, D.C. — Patients For Affordable Drugs released a new analysis showing that drugmakers are raising prices on lifesaving oncology medications while lobbying to delay Medicare Drug Price Negotiation programs — reinforcing a pattern of price hikes alongside efforts to weaken reforms. In the […]

Press Releases

New P4AD Analysis: Drugmakers Hike Prices Following Reconciliation Package that Weakened Medicare Negotiation for Rare Disease Drugs

Analysis is part of a new series on Pharma-driven price hikes of essential medicines WASHINGTON, D.C. — Patients For Affordable Drugs is releasing a new analysis finding that pharmaceutical companies raised prices on rare disease drugs just a few months after the passage of the ORPHAN Cures Act in the 2025 Reconciliation Package, which weakened […]

Press Releases

P4AD Files Sixth Amicus Brief Defending Medicare Negotiation, Amplifying Patient Voices Against Teva’s Appeal

WASHINGTON, D.C. — Patients For Affordable Drugs (P4AD) filed its sixth patient-centered amicus brief defending the Medicare Negotiation Program, this time in the District of Columbia U.S. Court of Appeals, where Teva Pharmaceuticals is appealing its failed attempt to strike down the program. The brief underscores the real-world impact of lower prices for patients and responds to legal […]

Reports

Big Pharma Hikes Prices on Rare Disease Drugs - As Medicare Protections are Weakened

Patients For Affordable Drugs is released a new analysis finding that pharmaceutical companies raised prices on rare disease drugs just a few months after the passage of the ORPHAN Cures Act in the 2025 Reconciliation Package.  Click here to download

Reports

Big Pharma Hikes Cancer Drugs for Americans

As Americans face growing anxiety about their ability to pay for health care in 2026, pharmaceutical corporations continue to raise prices on some of the most expensive drugs on the market: cancer treatments Click here to download